The CRISPR system is a revolutionary genome editing tool that has the potential to
revolutionize the field of cancer research and therapy. The ability to precisely target and edit …

Genomic analysis has greatly influenced the diagnosis and clinical management of patients
affected by diverse forms of hematologic malignancies. Here, we review how genetic …

T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the
bone marrow, mediastinum, central nervous system, and lymphoid organs. They account for …

T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignancy of immature T cells.
Recently, the next-generation sequencing approach has allowed systematic identification of …

We developed cis-X, a computational method for discovering regulatory noncoding variants
in cancer by integrating whole-genome and transcriptome sequencing data from a single …

T-lineage acute lymphoblastic leukaemia (T-ALL) is a high-risk tumour that has eluded
comprehensive genomic characterization, which is partly due to the high frequency of …

In acute myeloid leukemia (AML) with inv (3)(q21; q26) or t (3; 3)(q21; q26), a translocated
GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML …

MYB is a transcription factor which was identified in birds as a viral oncogene (v-MYB). Its
cellular counterpart was subsequently isolated as c-MYB which has three functional …

Cell competition has recently emerged as an important tumor suppressor mechanism in the
thymus that inhibits autonomous thymic maintenance. Here, we show that the oncogenic …

T-cell acute lymphocytic leukemia protein 1 (TAL1) is one of the most frequently deregulated
oncogenes in T-cell acute lymphoblastic leukemia (T-ALL). Its deregulation can occur …